Show Me the Data®: From Mutation to Action—KRAS as a Therapeutic Target in PDAC

Highlights from the PER® CME activity "Show Me the Data®: From Mutation to Action—KRAS as a Therapeutic Target in PDAC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts E. Gabriela Chiorean, MD; Tanios S. Bekaii-Saab, MD; Mitesh Borad, MD; and Christopher Lieu, MD, discuss the evolving role of KRAS-targeted therapies in pancreatic cancer, including underlying biology, emerging clinical data, and real-world challenges in treatment selection and trial access.

Earn CME credit by completing the full accredited activity (available through May 1, 2027):
https://www.gotoper.com/sogo26pdac-activity

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from Revolution Medicines.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.